SGLT2 inhibitors have been shown to reduce major adverse cardiovascular events (MACE, a composite endpoint of myocardial infarction, stroke and cardiovascular death) and hospitalization for heart failure in large clinical trials in patients with type 2 diabetes at high cardiovascular risk. The gene discussed is SLC5A2; the disease is heart failure.